for whom HPV vaccination is recommended—girls and
boys at age 11 or 12—were to be vaccinated ( 81). However,
the most recent estimates from the CDC show that in 2014,
only 40 percent of girls ages 13 to 17 and 24 percent of boys
of the same age had received the full course of three or more
doses of an HPV vaccine ( 82). This low coverage stands
in stark contrast to three-dose HPV vaccine coverage in
other countries ( 81, 83) (see Figure 7).
Several steps to address the low HPV vaccine coverage
in the United States were recently recommended by
the National Vaccine Advisory Committee (NVAC), a
federal advisory committee that provides vaccine and
immunization policy recommendations to the U.S.
Department of Health and Human Services ( 85). Among
the objectives outlined by the NVAC was the development
of comprehensive communication strategies for physicians
to encourage HPV vaccination at every opportunity.
The need for these strategies is highlighted by recent
data showing that many physicians recommend HPV
vaccination inconsistently, behind schedule, or without
urgency ( 86).
IN NEED OF A BOOST FIGURE 7
The percentage of adolescent girls in the United States to
have received the recommended three doses of the human
papillomavirus (HPV) vaccine is very low compared with
the percentages vaccinated in other high-income countries,
such as Australia and the United Kingdom. Rwanda, a low-
income country, has implemented a national, multisector,
collaborative, school-based HPV vaccination program ( 81, 83).
A trial of a school-based HPV vaccination program in Molepole,
a traditional village in Botswana with a population of more
than 60,000, was recently reported to have led to 79 percent
of eligible girls receiving three doses of the HPV vaccine and
to a nationwide rollout of the program in 2015 ( 84).
(age 15, 2011)
(grade 6, 2011)
(age 9 or older in
grades 4–6, 2013)
noninstitutionalized U.S. adults
were estimated to be chronically
infected with HBV ( 79).